Combination treatment with antibody-drug conjugates and cytarabine
AssigneeImmunoGen, Inc.
InventorsSharlene Adams, Callum M. Sloss, Patrick Zweidler-McKay
Life of this patent
Estimating the term…
Abstract
The present invention provides a method of treating a cancer in a subject comprising administering to the subject an effective amount of a CD33-targeted antibody-drug conjugate (ADC) and an effective amount of cytarabine. Also provided are pharmaceutical compositions comprising an effective amount of a CD33-targeted ADC and an effective amount of cytarabine.
Claims26
A method of treating a cancer in a subject comprising administering to the subject an effective amount of cytarabine and an effective amount of an antibody-drug conjugate of Formula (I):
- or a pharmaceutically acceptable salt thereof, wherein:
- the double line between N and C represents a single bond or a double bond, provided that when it is a double bond, X is absent and Y is hydrogen, when it is a single bond, X is hydrogen and Y is —SO3H;
- Ab is an anti-CD33 antibody or antigen-binding fragment thereof comprising a heavy chain variable region (VH) complementary determining region (CDR)1 sequence of SEQ ID NO:1, a VH CDR2 sequence of SEQ ID NO:2, and a VH CDR3 sequence of SEQ ID NO:3, and a light chain variable region (VL) CDR1 sequence of SEQ ID NO:4, a VL CDR2 sequence of SEQ ID NO:5, and a VL CDR3 sequence of SEQ ID NO:6;
- and
- r is an integer from 1 to 10.
(canceled)
(canceled)
(canceled)
28-29. (canceled)
31-34. (canceled)
A pharmaceutical composition comprising:
- i) an effective amount of cytarabine;
- ii) an effective amount of an antibody-drug conjugate of Formula (I):
- or a pharmaceutically acceptable salt thereof;
- and iii) a pharmaceutically acceptable carrier or diluent;
- wherein:
- the double line between N and C represents a single bond or a double bond, provided that when it is a double bond, X is absent and Y is hydrogen, when it is a single bond, X is hydrogen, Y is —SO3H;
- Ab is an anti-CD33 antibody or antigen-binding fragment thereof comprising a heavy chain variable region (VH) complementary determining region (CDR)1 sequence of SEQ ID NO:1, a VH CDR2 sequence of SEQ ID NO:2, and a VH CDR3 sequence of SEQ ID NO:3, and a light chain variable region (VL) CDR1 sequence of SEQ ID NO:4, a VL CDR2 sequence of SEQ ID NO:5, and a VL CDR3 sequence of SEQ ID NO:6;
- and
- r is an integer from 1 to 10.
36-46. (canceled)
Dependencies are inferred from the claim text.